Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus MYCHEL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus MYCHEL S.
DIFICID vs MYCHEL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
200 mg (tablet) orally twice daily for 10 days.
200 mg orally every 12 hours for 14 days
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Antibiotic
Antibiotic